{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T15:12:35Z","timestamp":1783696355358,"version":"3.55.0"},"reference-count":57,"publisher":"Becaris Publishing Limited","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:p>\n                    <jats:bold>Aim:<\/jats:bold>\n                    Network meta-analyses (NMAs) of seasonal vaccines face distinct challenges that can compromise the validity and relevance of findings. While established frameworks offer guidance for evaluating the feasibility of NMAs, they do not address factors specific to seasonal vaccines. This study aims to highlight unique methodological challenges related to conducting NMA feasibility assessments of seasonal vaccines. The considerations are framed to be compatible with existing guidance and recommendations for the conduct and reporting of NMAs.\n                    <jats:bold>Materials &amp; methods:<\/jats:bold>\n                    We developed a set of key considerations that should be applied when assessing the feasibility and\/or validity of NMAs comparing seasonal vaccines. The considerations were based on systematic reviews and critical appraisals of published NMAs of seasonal vaccines, hands-on experience performing feasibility assessments of seasonal vaccines, and input from consultations with vaccine experts.\n                    <jats:bold>Results:<\/jats:bold>\n                    Unique considerations for evaluating comparability across seasonal vaccine studies include: whether vaccines should be compared by platform, formulation, dose, and\/or valence; the impact of seasonality, strain evolution and definitions of placebo\/unvaccinated controls on network connectivity; target population characteristics including history and recency of prior vaccination and\/or infection(s), and baseline infection\/severe disease risk; antigenic match (i.e., the degree of concordance between vaccine composition and circulating viral strains), which directly influences effectiveness and outcome measurement approaches that consider time varying epidemiology and assay and measure discrepancy. Comprehensively integrating these elements into existing guidance frameworks ensures transparent assessment of the key assumptions underlying NMA (i.e., transitivity and homogeneity) within the context of unique study design and methodological features of seasonal vaccine studies.\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    The concepts highlighted in this paper address important gaps in the feasibility assessment process for NMAs of seasonal vaccines, which are crucial for informing public health decisions and guiding vaccine policy and implementation.\n                  <\/jats:p>","DOI":"10.57264\/cer-2026-0014","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T12:34:16Z","timestamp":1782736456000},"source":"Crossref","is-referenced-by-count":0,"title":["Considerations for assessing the feasibility of network meta-analysis of seasonal vaccines"],"prefix":"10.57264","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8528-9901","authenticated-orcid":false,"given":"Allie","family":"Cichewicz","sequence":"first","affiliation":[{"name":"Thermo Fisher Scientific, Waltham, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0557-3946","authenticated-orcid":false,"given":"Marissa","family":"Betts","sequence":"additional","affiliation":[{"name":"Thermo Fisher Scientific, Waltham, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3992-9549","authenticated-orcid":false,"given":"Narcisa","family":"Mesaros","sequence":"additional","affiliation":[{"name":"Thermo Fisher Scientific, Zaventem, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1269-4276","authenticated-orcid":false,"given":"Heather","family":"Burnett","sequence":"additional","affiliation":[{"name":"Heather Burnett HEOR, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"issue":"1","key":"e_1_3_7_3_2","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s12325-024-03013-6","article-title":"Indirect treatment comparisons in healthcare decision making: a targeted review of regulatory approval, reimbursement, and pricing recommendations globally for oncology drugs in 2021\u20132023","volume":"42","author":"Igarashi A","year":"2025","unstructured":"Igarashi A, Tanaka S, De Moor R Indirect treatment comparisons in healthcare decision making: a targeted review of regulatory approval, reimbursement, and pricing recommendations globally for oncology drugs in 2021\u20132023. Adv. Ther. 42(1), 52\u201369 (2025).","journal-title":"Adv. Ther."},{"key":"e_1_3_7_4_2","unstructured":"National Institute for Health and Care Excellence. NICE technology appraisal and highly specialised technologies guidance: the manual (2022). (Accessed 10 May 2026). https:\/\/www.nice.org.uk\/process\/pmg36\/resources\/nice-technology-appraisal-and-highly-specialised-technologies-guidance-the-manual-pdf-72286779244741"},{"issue":"4","key":"e_1_3_7_5_2","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jval.2011.01.011","article-title":"Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2","volume":"14","author":"Hoaglin DC","year":"2011","unstructured":"Hoaglin DC, Hawkins N, Jansen JP Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health 14(4), 429\u2013437 (2011).","journal-title":"Value Health"},{"issue":"5","key":"e_1_3_7_6_2","doi-asserted-by":"crossref","first-page":"371","DOI":"10.4097\/kja.21358","article-title":"Concepts and emerging issues of network meta-analysis","volume":"74","author":"Ahn E","year":"2021","unstructured":"Ahn E, Kang H. Concepts and emerging issues of network meta-analysis. Korean J. Anesthesiol. 74(5), 371\u2013382 (2021).","journal-title":"Korean J. Anesthesiol."},{"key":"e_1_3_7_7_2","unstructured":"Dias S Sutton AJ Welton NJ Ades AE. NICE DSU technical support document 3: heterogeneity: subgroups meta-regression bias and bias-adjustment (2011). (Accessed 11 May 2025). http:\/\/www.nicedsu.org.uk\/"},{"key":"e_1_3_7_8_2","unstructured":"Member State Coordination Group on Health Technology Assessment (HTA CG). Methodological Guideline for Quantitative Evidence Synthesis: Direct and Indirect Comparisons (2024). (Accessed 18 January 2026). https:\/\/health.ec.europa.eu\/document\/download\/4ec8288e-6d15-49c5-a490-d8ad7748578f_en?filename=hta_methodological-guideline_direct-indirect-comparisons_en.pdf"},{"key":"e_1_3_7_9_2","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/1741-7015-12-93","article-title":"A process for assessing the feasibility of a network meta-analysis: a case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer","volume":"12","author":"Cope S","year":"2014","unstructured":"Cope S, Zhang J, Saletan S, Smiechowski B, Jansen JP, Schmid P. A process for assessing the feasibility of a network meta-analysis: a case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer. BMC Med. 12, 93 (2014).","journal-title":"BMC Med."},{"issue":"2","key":"e_1_3_7_10_2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3390\/jmahp13020031","article-title":"Opportunities for and challenges of conducting indirect treatment comparisons and meta-analyses for vaccines in post-EU HTA regulation era","volume":"13","author":"Graham C","year":"2025","unstructured":"Graham C, Barker E, Moss J Opportunities for and challenges of conducting indirect treatment comparisons and meta-analyses for vaccines in post-EU HTA regulation era. JMAHP 13(2), 31 (2025).","journal-title":"JMAHP"},{"issue":"6","key":"e_1_3_7_11_2","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1080\/14760584.2019.1622419","article-title":"Challenges in estimating influenza vaccine effectiveness","volume":"18","author":"Ainslie KEC","year":"2019","unstructured":"Ainslie KEC, Haber M, Orenstein WA. Challenges in estimating influenza vaccine effectiveness. Expert Rev. Vaccines 18(6), 615\u2013628 (2019).","journal-title":"Expert Rev. Vaccines"},{"issue":"4","key":"e_1_3_7_12_2","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1080\/03007995.2025.2466726","article-title":"Indirect comparison of the relative vaccine effectiveness of mRNA-1283 vs. BNT162b2 vaccines against symptomatic COVID-19 among US adults","volume":"41","author":"Beck E","year":"2025","unstructured":"Beck E, Georgieva M, Wang W-J Indirect comparison of the relative vaccine effectiveness of mRNA-1283 vs. BNT162b2 vaccines against symptomatic COVID-19 among US adults. Curr. Med. Res. Opin. 41(4), 721\u2013732 (2025).","journal-title":"Curr. Med. Res. Opin."},{"key":"e_1_3_7_13_2","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2025.2505754"},{"issue":"12","key":"e_1_3_7_14_2","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1111\/jgs.19176","article-title":"Protection against influenza hospitalizations from enhanced influenza vaccines among older adults: a systematic review and network meta-analysis","volume":"72","author":"Ferdinands JM","year":"2024","unstructured":"Ferdinands JM, Blanton LH, Alyanak E Protection against influenza hospitalizations from enhanced influenza vaccines among older adults: a systematic review and network meta-analysis. J. Am. Geriatr. Soc. 72(12), 3875\u20133889 (2024).","journal-title":"J. Am. Geriatr. Soc."},{"issue":"4","key":"e_1_3_7_15_2","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1136\/bmjebm-2023-112767","article-title":"Trivalent and quadrivalent seasonal influenza vaccine in adults aged 60 and older: a systematic review and network meta-analysis","volume":"29","author":"Veroniki AA","year":"2024","unstructured":"Veroniki AA, Thirugnanasampanthar SS, Konstantinidis M Trivalent and quadrivalent seasonal influenza vaccine in adults aged 60 and older: a systematic review and network meta-analysis. BMJ Evid. Based Med. 29(4), 239\u2013254 (2024).","journal-title":"BMJ Evid. Based Med."},{"issue":"9","key":"e_1_3_7_16_2","doi-asserted-by":"crossref","first-page":"A777","DOI":"10.1016\/j.jval.2017.08.2244","article-title":"Network meta-analysis in the evaluation of vaccines","volume":"20","author":"McGirr A","year":"2017","unstructured":"McGirr A, Widenmaier R, Burnett H Network meta-analysis in the evaluation of vaccines. Value Health 20(9), A777 (2017).","journal-title":"Value Health"},{"key":"e_1_3_7_17_2","unstructured":"Institute for Clinical and Economic Review. Vaccines for Covid-19: draft background and scope (2025). (Accessed 11 May 2026). https:\/\/icer.org\/wp-content\/uploads\/2025\/11\/ICER_Covid-19_Draft-Scope_For-Publication_111025.pdf?"},{"key":"e_1_3_7_18_2","article-title":"Vaccines for Covid-19: effectiveness and value; draft evidence report","author":"Rind DM","year":"2026","unstructured":"Rind DM, McQueen RB, Zemplenyi A Vaccines for Covid-19: effectiveness and value; draft evidence report. Inst. Clin.Econ. Rev. (2026). (Accessed 9 May 2026). https:\/\/icer.org\/assessment\/covid-19-2025\/","journal-title":"Inst. Clin.Econ. Rev."},{"key":"e_1_3_7_19_2","article-title":"EFLUELDA (vaccin grippal trivalent inactiv\u00e9 haute dose): immunisation active des personnes \u00e2g\u00e9es de 60 ans et plus pour lesquelles la vaccination grippale est recommand\u00e9e","author":"Haute Autorit\u00e9 de Sant\u00e9","year":"2025","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. EFLUELDA (vaccin grippal trivalent inactiv\u00e9 haute dose): immunisation active des personnes \u00e2g\u00e9es de 60 ans et plus pour lesquelles la vaccination grippale est recommand\u00e9e. Haute Autorit\u00e9 de Sant\u00e9 (2025). Available from: https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2025-05\/efluelda_avis_economique_ceesp_795.pdf","journal-title":"Haute Autorit\u00e9 de Sant\u00e9"},{"key":"e_1_3_7_20_2","unstructured":"World Health Organization. Evaluation of COVID-19 vaccine effectiveness in a changing landscape of COVID-19 epidemiology and vaccination (2022). https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-vaccine_effectiveness-VE_evaluations-2022.1"},{"issue":"49","key":"e_1_3_7_21_2","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.15585\/mmwr.mm7349a2","article-title":"Use of additional doses of 2024\u20132025 COVID-19 vaccine for adults aged \u226565 years and persons aged \u22656 months with moderate or severe immunocompromise: recommendations of the Advisory Committee on Immunization Practices \u2014 United States, 2024","volume":"73","author":"Roper LE","year":"2024","unstructured":"Roper LE, Godfrey M, Link-Gelles R Use of additional doses of 2024\u20132025 COVID-19 vaccine for adults aged \u226565 years and persons aged \u22656 months with moderate or severe immunocompromise: recommendations of the Advisory Committee on Immunization Practices \u2014 United States, 2024. Morb. Mortal. Wkly Rep. 73(49), 1118\u20131123 (2024).","journal-title":"Morb. Mortal. Wkly Rep."},{"issue":"32","key":"e_1_3_7_22_2","doi-asserted-by":"crossref","first-page":"500","DOI":"10.15585\/mmwr.mm7432a2","article-title":"Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices \u2014 United States, 2025\u201326 Influenza Season","volume":"74","author":"Grohskopf LA","year":"2025","unstructured":"Grohskopf LA, Blanton LH, Ferdinands JM, Reed C, Dugan VG, Daskalakis DC. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices \u2014 United States, 2025\u201326 Influenza Season. Morb. Mortal. Wkly Rep. 74(32), 500\u2013507 (2025).","journal-title":"Morb. Mortal. Wkly Rep."},{"key":"e_1_3_7_23_2","unstructured":"Higgins J Thomas J Chandler J Cochrane Handbook for Systematic Reviews of Interventions (Version 5.5 Edition [updated August 2024]). Cochrane. (Accessed 11 May 2025). www.cochrane.org\/handbook"},{"issue":"24","key":"e_1_3_7_24_2","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMsb2506929","article-title":"An evidence-based approach to Covid-19 vaccination","volume":"392","author":"Prasad V","year":"2025","unstructured":"Prasad V, Makary MA. An evidence-based approach to Covid-19 vaccination. N. Engl. J. Med. 392(24), 2484\u20132486 (2025).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_7_25_2","volume-title":"Research Ethics","author":"Concato J","year":"2008","unstructured":"Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. In: Research Ethics. Routledge (2008)."},{"issue":"5","key":"e_1_3_7_26_2","doi-asserted-by":"crossref","first-page":"e2310650","DOI":"10.1001\/jamanetworkopen.2023.10650","article-title":"Evaluation of waning of SARS-CoV-2 vaccine-induced immunity: a systematic review and meta-analysis","volume":"6","author":"Menegale F","year":"2023","unstructured":"Menegale F, Manica M, Zardini A Evaluation of waning of SARS-CoV-2 vaccine-induced immunity: a systematic review and meta-analysis. JAMA Netw. Open 6(5), e2310650 (2023).","journal-title":"JAMA Netw. Open"},{"key":"e_1_3_7_27_2","volume-title":"Seasonal Influenza Vaccines: an Overview for Decision-Makers. (1st Edition)","author":"World Health Organization","year":"2020","unstructured":"World Health Organization. Seasonal Influenza Vaccines: an Overview for Decision-Makers. (1st Edition). World Health Organization, Switzerland (2020)."},{"key":"e_1_3_7_28_2","unstructured":"World Health Organization. WHO roadmap on uses of COVID-19 vaccines in the context of Omicron and high population immunity (2023). https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-Vaccines-SAGE-Prioritization-2023.2"},{"issue":"3","key":"e_1_3_7_29_2","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/cid\/ciaa706","article-title":"Effects of prior season vaccination on current season vaccine effectiveness in the United States Flu Vaccine Effectiveness Network, 2012\u20132013 Through 2017\u20132018","volume":"73","author":"Kim SS","year":"2021","unstructured":"Kim SS, Flannery B, Foppa IM Effects of prior season vaccination on current season vaccine effectiveness in the United States Flu Vaccine Effectiveness Network, 2012\u20132013 Through 2017\u20132018. Clin. Infect. Dis. 73(3), 497\u2013505 (2021).","journal-title":"Clin. Infect. Dis."},{"issue":"2","key":"e_1_3_7_30_2","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3201\/eid2802.211727","article-title":"Viral interference between respiratory viruses","volume":"28","author":"Piret J","year":"2022","unstructured":"Piret J, Boivin G. Viral interference between respiratory viruses. Emerg. Infect. Dis. 28(2), 273\u2013281 (2022).","journal-title":"Emerg. Infect. Dis."},{"issue":"12","key":"e_1_3_7_31_2","doi-asserted-by":"crossref","first-page":"e0294688","DOI":"10.1371\/journal.pone.0294688","article-title":"Socioeconomic inequalities in vaccine uptake: a global umbrella review","volume":"18","author":"Sacre A","year":"2023","unstructured":"Sacre A, Bambra C, Wildman JM Socioeconomic inequalities in vaccine uptake: a global umbrella review. PLoS ONE 18(12), e0294688 (2023).","journal-title":"PLoS ONE"},{"issue":"10","key":"e_1_3_7_32_2","doi-asserted-by":"crossref","first-page":"ofae598","DOI":"10.1093\/ofid\/ofae598","article-title":"Quantifying and adjusting for confounding from health-seeking behavior and health care access in observational research","volume":"11","author":"Graham S","year":"2024","unstructured":"Graham S, Walker JL, Andrews N Quantifying and adjusting for confounding from health-seeking behavior and health care access in observational research. Open Forum Infect. Dis. 11(10), ofae598 (2024).","journal-title":"Open Forum Infect. Dis."},{"issue":"36","key":"e_1_3_7_33_2","doi-asserted-by":"crossref","first-page":"4796","DOI":"10.1016\/j.vaccine.2017.07.003","article-title":"Basic principles of test-negative design in evaluating influenza vaccine effectiveness","volume":"35","author":"Fukushima W","year":"2017","unstructured":"Fukushima W, Hirota Y. Basic principles of test-negative design in evaluating influenza vaccine effectiveness. Vaccine 35(36), 4796\u20134800 (2017).","journal-title":"Vaccine"},{"issue":"8","key":"e_1_3_7_34_2","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1038\/s41591-022-01877-1","article-title":"Rapid evaluation of COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 variants by analysis of genetic distance","volume":"28","author":"Cao L","year":"2022","unstructured":"Cao L, Lou J, Chan SY Rapid evaluation of COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 variants by analysis of genetic distance. Nat. Med. 28(8), 1715\u20131722 (2022).","journal-title":"Nat. Med."},{"key":"e_1_3_7_35_2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12982-024-00140-x","article-title":"Evolution and implications of SARS-CoV-2 variants in the post-pandemic era","volume":"21","author":"Manirambona E","year":"2024","unstructured":"Manirambona E, John Okesanya O, Olabode Olaleke N, Adebimpe Oso T, Eliseo Lucero-Prisno D. Evolution and implications of SARS-CoV-2 variants in the post-pandemic era. Discover Public Health 21, 16 (2024).","journal-title":"Discover Public Health"},{"key":"e_1_3_7_36_2","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/1741-7015-11-153","article-title":"Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis","volume":"11","author":"Tricco AC","year":"2013","unstructured":"Tricco AC, Chit A, Soobiah C Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis. BMC Med. 11, 153 (2013).","journal-title":"BMC Med."},{"key":"e_1_3_7_37_2","unstructured":"GISAID. hCoV-19 (SARS-CoV-2) variants and lineages (2025). https:\/\/gisaid.org\/hcov-19-variants-dashboard\/"},{"issue":"8","key":"e_1_3_7_38_2","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/S1473-3099(22)00409-1","article-title":"Duration of effectiveness of vaccination against COVID-19 caused by the omicron variant","volume":"22","author":"Higdon MM","year":"2022","unstructured":"Higdon MM, Baidya A, Walter KK Duration of effectiveness of vaccination against COVID-19 caused by the omicron variant. Lancet Infect. Dis. 22(8), 1114\u20131116 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"e_1_3_7_39_2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.smim.2018.10.010","article-title":"Vaccination in the elderly: the challenge of immune changes with aging","volume":"40","author":"Ciabattini A","year":"2018","unstructured":"Ciabattini A, Nardini C, Santoro F, Garagnani P, Franceschi C, Medaglini D. Vaccination in the elderly: the challenge of immune changes with aging. Semin. Immunol. 40, 83\u201394 (2018).","journal-title":"Semin. Immunol."},{"key":"e_1_3_7_40_2","doi-asserted-by":"crossref","first-page":"127567","DOI":"10.1016\/j.vaccine.2025.127567","article-title":"Analytical approaches and examples of addressing time-varying factors in COVID-19 vaccine effectiveness studies: report from a meeting of the World Health Organization","volume":"62","author":"Varma A","year":"2025","unstructured":"Varma A, Andrews NJ, Carazo S Analytical approaches and examples of addressing time-varying factors in COVID-19 vaccine effectiveness studies: report from a meeting of the World Health Organization. Vaccine 62, 127567 (2025).","journal-title":"Vaccine"},{"issue":"1","key":"e_1_3_7_41_2","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/irv.12786","article-title":"Assessment of the benefits of seasonal influenza vaccination: elements of a framework to interpret estimates of vaccine effectiveness and support robust decision-making and communication","volume":"15","author":"Hollingsworth R","year":"2021","unstructured":"Hollingsworth R, El Guerche-S\u00e9blain C, Tsai T Assessment of the benefits of seasonal influenza vaccination: elements of a framework to interpret estimates of vaccine effectiveness and support robust decision-making and communication. Influenza Other Respir. Viruses 15(1), 164\u2013174 (2021).","journal-title":"Influenza Other Respir. Viruses"},{"issue":"1","key":"e_1_3_7_42_2","doi-asserted-by":"crossref","first-page":"e564","DOI":"10.1093\/cid\/ciac234","article-title":"Effects of confounding bias in coronavirus disease 2019 (COVID-19) and influenza vaccine effectiveness test-negative designs due to correlated influenza and COVID-19 vaccination behaviors","volume":"75","author":"Doll MK","year":"2022","unstructured":"Doll MK, Pettigrew SM, Ma J, Verma A. Effects of confounding bias in coronavirus disease 2019 (COVID-19) and influenza vaccine effectiveness test-negative designs due to correlated influenza and COVID-19 vaccination behaviors. Clin. Infect. Dis. 75(1), e564\u2013e571 (2022).","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"e_1_3_7_43_2","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1080\/14760584.2025.2569037","article-title":"Indirect comparison of the immunogenicity of 15-valent and 20-valent pneumococcal conjugate vaccines in children using a 2 + 1 schedule","volume":"24","author":"Mt-Isa S","year":"2025","unstructured":"Mt-Isa S, Chumbley JR, Kelly MS, Weaver J, Banniettis N. Indirect comparison of the immunogenicity of 15-valent and 20-valent pneumococcal conjugate vaccines in children using a 2 + 1 schedule. Expert Rev. Vaccines 24(1), 946\u2013957 (2025).","journal-title":"Expert Rev. Vaccines"},{"key":"e_1_3_7_44_2","volume-title":"Guideline on clinical evaluation of vaccines","author":"European Medicines Agency, Committee for Medicinal Products for Human Use","year":"2023","unstructured":"European Medicines Agency, Committee for Medicinal Products for Human Use. Guideline on clinical evaluation of vaccines. European Medicines Agency, The Netherlands (2023)."},{"issue":"9","key":"e_1_3_7_45_2","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/j.vaccine.2024.02.071","article-title":"Four statistical frameworks for assessing an immune correlate of protection (surrogate endpoint) from a randomized, controlled, vaccine efficacy trial","volume":"42","author":"Gilbert PB","year":"2024","unstructured":"Gilbert PB, Fong Y, Hejazi NS Four statistical frameworks for assessing an immune correlate of protection (surrogate endpoint) from a randomized, controlled, vaccine efficacy trial. Vaccine 42(9), 2181\u20132190 (2024).","journal-title":"Vaccine"},{"issue":"11","key":"e_1_3_7_46_2","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1016\/j.vaccine.2020.01.088","article-title":"Comparison of influenza-specific neutralizing antibody titers determined using different assay readouts and hemagglutination inhibition titers: good correlation but poor agreement","volume":"38","author":"Sicca F","year":"2020","unstructured":"Sicca F, Martinuzzi D, Montomoli E, Huckriede A. Comparison of influenza-specific neutralizing antibody titers determined using different assay readouts and hemagglutination inhibition titers: good correlation but poor agreement. Vaccine 38(11), 2527\u20132541 (2020).","journal-title":"Vaccine"},{"key":"e_1_3_7_47_2","volume-title":"COVID-19 Vaccines: Safety Surveillance Manual.","author":"World Health Organization","year":"2020","unstructured":"World Health Organization. COVID-19 Vaccines: Safety Surveillance Manual.. 1st edition. World Health Organization, Switzerland (2020).","edition":"1"},{"key":"e_1_3_7_48_2","unstructured":"US Food and Drug Administration. Development and licensure of vaccines to prevent COVID-19: guidance for industry (2023). (Accessed 11 May 2026). https:\/\/www.fda.gov\/media\/139638\/download"},{"issue":"26","key":"e_1_3_7_49_2","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1002\/sim.9562","article-title":"Network meta-analysis of rare events using penalized likelihood regression","volume":"41","author":"Evrenoglou T","year":"2022","unstructured":"Evrenoglou T, White IR, Afach S, Mavridis D, Chaimani A. Network meta-analysis of rare events using penalized likelihood regression. Stat. Med. 41(26), 5203\u20135219 (2022).","journal-title":"Stat. Med."},{"issue":"5","key":"e_1_3_7_50_2","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1056\/NEJMra1614394","article-title":"Evidence for health decision making \u2013 beyond randomized, controlled trials","volume":"377","author":"Frieden TR","year":"2017","unstructured":"Frieden TR. Evidence for health decision making \u2013 beyond randomized, controlled trials. N. Engl. J. Med. 377(5), 465\u2013475 (2017).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_7_51_2","doi-asserted-by":"crossref","first-page":"101750","DOI":"10.1016\/j.biologicals.2024.101750","article-title":"The role of real-world evidence for regulatory and public health decision-making for accelerated vaccine deployment \u2013 a meeting report","volume":"85","author":"Bollaerts K","year":"2024","unstructured":"Bollaerts K, Wyndham-Thomas C, Miller E The role of real-world evidence for regulatory and public health decision-making for accelerated vaccine deployment \u2013 a meeting report. Biologicals 85, 101750 (2024).","journal-title":"Biologicals"},{"issue":"1","key":"e_1_3_7_52_2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/14760584.2023.2290194","article-title":"Real world evidence for public health decision-making on vaccination policies: perspectives from an expert roundtable","volume":"23","author":"de Waure C","year":"2024","unstructured":"de Waure C, G\u00e4rtner BC, Lopalco PL, Puig-Barbera J, Nguyen-Van-Tam JS. Real world evidence for public health decision-making on vaccination policies: perspectives from an expert roundtable. Expert Rev. Vaccines 23(1), 27\u201338 (2024).","journal-title":"Expert Rev. Vaccines"},{"key":"e_1_3_7_53_2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/2046-4053-1-41","article-title":"Sample size and power considerations in network meta-analysis","volume":"1","author":"Thorlund K","year":"2012","unstructured":"Thorlund K, Mills EJ. Sample size and power considerations in network meta-analysis. Syst. Rev. 1, 41 (2012).","journal-title":"Syst. Rev."},{"issue":"6","key":"e_1_3_7_54_2","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1136\/bmjebm-2021-111901","article-title":"Factors influencing estimated effectiveness of COVID-19 vaccines in non-randomised studies","volume":"27","author":"Ioannidis JPA","year":"2022","unstructured":"Ioannidis JPA. Factors influencing estimated effectiveness of COVID-19 vaccines in non-randomised studies. BMJ Evid. Based Med. 27(6), 324\u2013329 (2022).","journal-title":"BMJ Evid. Based Med."},{"key":"e_1_3_7_55_2","doi-asserted-by":"crossref","first-page":"1474045","DOI":"10.3389\/fmed.2024.1474045","article-title":"Biases in COVID-19 vaccine effectiveness studies using cohort design","volume":"11","author":"Agampodi S","year":"2024","unstructured":"Agampodi S, Tadesse BT, Sahastrabuddhe S, Excler J-L, Kim JH. Biases in COVID-19 vaccine effectiveness studies using cohort design. Front. Med. (Lausanne) 11, 1474045 (2024).","journal-title":"Front. Med. (Lausanne)"},{"issue":"2","key":"e_1_3_7_56_2","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3390\/vaccines10020313","article-title":"Adverse events reporting quality of randomized controlled trials of COVID-19 vaccine using the CONSORT criteria for reporting harms: a systematic review","volume":"10","author":"Yuniar CT","year":"2022","unstructured":"Yuniar CT, Pratiwi B, Ihsan AF Adverse events reporting quality of randomized controlled trials of COVID-19 vaccine using the CONSORT criteria for reporting harms: a systematic review. Vaccines (Basel) 10(2), 313 (2022).","journal-title":"Vaccines (Basel)"},{"issue":"2","key":"e_1_3_7_57_2","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.amjmed.2024.10.007","article-title":"Characteristics of vaccine safety observational studies and authors' attitudes: a systematic review","volume":"138","author":"Barosa M","year":"2025","unstructured":"Barosa M, Prasad V. Characteristics of vaccine safety observational studies and authors' attitudes: a systematic review. Am. J. Med. 138(2), 254\u2013261.e5 (2025).","journal-title":"Am. J. Med."},{"issue":"1","key":"e_1_3_7_58_2","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41541-024-00872-6","article-title":"Realising the potential of correlates of protection for vaccine development, licensure and use: short summary","volume":"9","author":"King DF","year":"2024","unstructured":"King DF, Groves H, Weller C Realising the potential of correlates of protection for vaccine development, licensure and use: short summary. NPJ Vaccines 9(1), 82 (2024).","journal-title":"NPJ Vaccines"},{"issue":"1","key":"e_1_3_7_59_2","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41392-021-00481-y","article-title":"Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need","volume":"6","author":"Jin P","year":"2021","unstructured":"Jin P, Li J, Pan H, Wu Y, Zhu F. Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need. Signal Transduct. Target Ther. 6(1), 48 (2021).","journal-title":"Signal Transduct. Target Ther."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2026-0014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T14:13:48Z","timestamp":1783692828000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2026-0014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":57,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.57264\/cer-2026-0014"],"URL":"https:\/\/doi.org\/10.57264\/cer-2026-0014","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"article-number":"e260014"}}